SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 305 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,402,000 | +9.8% | 448,795 | +3.7% | 0.02% | +15.4% |
| Q2 2023 | $49,558,000 | +0.6% | 432,744 | +21.1% | 0.01% | -7.1% |
| Q1 2023 | $49,240,000 | +24.5% | 357,240 | +17.0% | 0.01% | +27.3% |
| Q4 2022 | $39,559,000 | +280.2% | 305,295 | +224.2% | 0.01% | +266.7% |
| Q3 2022 | $10,406,000 | +39.9% | 94,157 | -5.1% | 0.00% | +50.0% |
| Q2 2022 | $7,439,000 | +38.5% | 99,244 | +44.4% | 0.00% | +100.0% |
| Q1 2022 | $5,370,000 | -19.0% | 68,727 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $6,626,000 | -13.1% | 73,594 | -10.8% | 0.00% | 0.0% |
| Q3 2021 | $7,628,000 | -46.7% | 82,495 | -55.1% | 0.00% | -50.0% |
| Q2 2021 | $14,299,000 | +238.4% | 183,928 | +224.5% | 0.00% | +300.0% |
| Q1 2021 | $4,225,000 | -66.2% | 56,685 | -22.6% | 0.00% | -75.0% |
| Q4 2020 | $12,490,000 | -24.4% | 73,257 | -37.7% | 0.00% | -33.3% |
| Q3 2020 | $16,512,000 | -2.7% | 117,576 | +11.1% | 0.01% | -14.3% |
| Q2 2020 | $16,973,000 | +135.0% | 105,860 | +43.4% | 0.01% | +133.3% |
| Q1 2020 | $7,223,000 | -42.9% | 73,835 | -24.7% | 0.00% | -40.0% |
| Q4 2019 | $12,653,000 | +106.1% | 98,056 | +20.3% | 0.01% | +150.0% |
| Q3 2019 | $6,138,000 | -47.8% | 81,493 | +5.4% | 0.00% | -60.0% |
| Q2 2019 | $11,748,000 | +26.3% | 77,319 | -0.9% | 0.01% | +25.0% |
| Q1 2019 | $9,303,000 | -31.2% | 78,060 | -37.0% | 0.00% | -33.3% |
| Q4 2018 | $13,519,000 | -44.4% | 123,878 | -17.7% | 0.01% | -40.0% |
| Q3 2018 | $24,297,000 | +16.5% | 150,443 | -4.7% | 0.01% | +11.1% |
| Q2 2018 | $20,861,000 | -2.5% | 157,828 | -45.4% | 0.01% | -10.0% |
| Q1 2018 | $21,405,000 | +30.3% | 288,894 | -2.2% | 0.01% | +42.9% |
| Q4 2017 | $16,431,000 | +321.4% | 295,322 | +243.6% | 0.01% | +250.0% |
| Q3 2017 | $3,899,000 | +786.1% | 85,949 | +558.5% | 0.00% | – |
| Q2 2017 | $440,000 | -18.2% | 13,052 | -28.1% | 0.00% | – |
| Q1 2017 | $538,000 | +220.2% | 18,156 | +195.4% | 0.00% | – |
| Q4 2016 | $168,000 | -5.1% | 6,147 | +112.6% | 0.00% | – |
| Q3 2016 | $177,000 | +132.9% | 2,891 | -27.8% | 0.00% | – |
| Q2 2016 | $76,000 | +7.0% | 4,006 | +11.2% | 0.00% | – |
| Q1 2016 | $71,000 | -73.8% | 3,601 | -48.8% | 0.00% | – |
| Q4 2015 | $271,000 | +22.6% | 7,029 | +2.2% | 0.00% | – |
| Q3 2015 | $221,000 | +68.7% | 6,877 | +60.3% | 0.00% | – |
| Q2 2015 | $131,000 | +125.9% | 4,290 | -3.1% | 0.00% | – |
| Q1 2015 | $58,000 | -17.1% | 4,425 | -8.2% | 0.00% | – |
| Q4 2014 | $70,000 | +45.8% | 4,820 | +107.2% | 0.00% | – |
| Q3 2014 | $48,000 | -31.4% | 2,326 | -0.9% | 0.00% | – |
| Q2 2014 | $70,000 | -86.9% | 2,346 | -89.5% | 0.00% | – |
| Q1 2014 | $536,000 | +1065.2% | 22,286 | +874.9% | 0.00% | – |
| Q4 2013 | $46,000 | -61.3% | 2,286 | -9.2% | 0.00% | – |
| Q3 2013 | $119,000 | -89.7% | 2,519 | -91.7% | 0.00% | -100.0% |
| Q2 2013 | $1,160,000 | – | 30,499 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |